Quantum BioPharma Ltd.
QNTM
$3.89
-$0.16-3.95%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 36.74% | 25.42% | 27.01% | 20.69% | 3.17% |
| Depreciation & Amortization | 8.68% | 11.27% | 5.86% | -4.03% | -66.58% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.92% | -5.17% | 67.28% | 76.31% | 42.47% |
| Operating Income | 13.92% | 5.17% | -67.28% | -76.31% | -42.47% |
| Income Before Tax | -48.26% | -80.73% | -158.40% | -240.09% | -108.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -48.26% | -80.73% | -158.40% | -240.09% | -108.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 17.99% | 9.65% | -76.99% | 26.89% | 33.20% |
| Net Income | -49.26% | -84.30% | -178.49% | -261.70% | -111.98% |
| EBIT | 13.92% | 5.17% | -67.28% | -76.31% | -42.47% |
| EBITDA | 14.59% | 5.68% | -70.08% | -80.52% | -57.83% |
| EPS Basic | 45.55% | 41.29% | 26.40% | -11.37% | 6.65% |
| Normalized Basic EPS | 42.56% | 36.36% | 15.88% | 3.67% | 9.53% |
| EPS Diluted | 45.55% | 41.29% | 26.40% | -11.37% | 6.68% |
| Normalized Diluted EPS | 42.56% | 36.36% | 15.88% | 3.67% | 9.53% |
| Average Basic Shares Outstanding | 151.73% | 216.30% | 306.51% | 241.31% | 148.36% |
| Average Diluted Shares Outstanding | 151.73% | 216.30% | 306.51% | 241.31% | 148.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |